CA2641564C - Use of kcnq-openers for treating or reducing the symptoms of schizophrenia - Google Patents

Use of kcnq-openers for treating or reducing the symptoms of schizophrenia Download PDF

Info

Publication number
CA2641564C
CA2641564C CA2641564A CA2641564A CA2641564C CA 2641564 C CA2641564 C CA 2641564C CA 2641564 A CA2641564 A CA 2641564A CA 2641564 A CA2641564 A CA 2641564A CA 2641564 C CA2641564 C CA 2641564C
Authority
CA
Canada
Prior art keywords
alk
cycloalk
halo
yloxy
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2641564A
Other languages
English (en)
French (fr)
Other versions
CA2641564A1 (en
Inventor
Henriette Husum Bak-Jensen
Christian Wenzel Tornoee
Mario Rottlaender
Daniel Rodriguez Greve
Nikolay Khanzhin
Andreas Ritzen
William Patrick Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38055396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2641564(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CA2641564A1 publication Critical patent/CA2641564A1/en
Application granted granted Critical
Publication of CA2641564C publication Critical patent/CA2641564C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2641564A 2006-02-07 2007-02-02 Use of kcnq-openers for treating or reducing the symptoms of schizophrenia Expired - Fee Related CA2641564C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77130406P 2006-02-07 2006-02-07
DKPA200600175 2006-02-07
US60/771,304 2006-02-07
DKPA200600175 2006-02-07
PCT/DK2007/050013 WO2007090409A1 (en) 2006-02-07 2007-02-02 Use of kcnq-openers for threating or reducing the symptoms of schizophrenia

Publications (2)

Publication Number Publication Date
CA2641564A1 CA2641564A1 (en) 2007-08-16
CA2641564C true CA2641564C (en) 2012-06-12

Family

ID=38055396

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2641564A Expired - Fee Related CA2641564C (en) 2006-02-07 2007-02-02 Use of kcnq-openers for treating or reducing the symptoms of schizophrenia

Country Status (16)

Country Link
US (1) US20090118285A1 (enExample)
EP (2) EP2554162A1 (enExample)
JP (1) JP2009525993A (enExample)
KR (1) KR20080096659A (enExample)
CN (1) CN101378742B (enExample)
AR (1) AR059319A1 (enExample)
AU (1) AU2007214128B2 (enExample)
BR (1) BRPI0707495A2 (enExample)
CA (1) CA2641564C (enExample)
EA (1) EA017915B1 (enExample)
IL (1) IL192745A0 (enExample)
MX (1) MX2008009655A (enExample)
NO (1) NO20083838L (enExample)
NZ (1) NZ569517A (enExample)
TW (1) TWI453013B (enExample)
WO (1) WO2007090409A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513196A (ja) * 2007-08-01 2011-04-28 ハー・ルンドベック・アクチエゼルスカベット ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのｋｃｎｑカリウムチャネル開口薬の使用
CA2804165C (en) 2010-07-08 2015-02-24 Pfizer Inc. Piperidinyl pyrimidine amides as kv7 potassium channel openers
WO2016077724A1 (en) * 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
US10590067B2 (en) 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
MA51881B1 (fr) 2018-02-20 2023-08-31 H Lundbeck As Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7
WO2019203951A1 (en) 2018-04-20 2019-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective potassium channel agonists
RS66130B1 (sr) 2019-08-02 2024-11-29 H Lundbeck As Derivati alkohola kao otvarači kv7 kalijumovih kanala
CN119490430A (zh) 2019-08-02 2025-02-21 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物
AR119521A1 (es) 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
US20230015539A1 (en) * 2019-12-06 2023-01-19 Icahn School Of Medicine At Mount Sinai Method of treatment with kcnq channel openers

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
JP4294142B2 (ja) 1999-02-02 2009-07-08 株式会社日立製作所 ディスクサブシステム
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
CA2438868A1 (en) * 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
JP2004535413A (ja) * 2001-05-31 2004-11-25 ブリストル−マイヤーズ　スクイブ　カンパニー Ｋｃｎｑカリウムチャンネルモジュレーターとしてのシンナミド誘導体
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
AU2003294442A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 3-heterocyclic benzylamide derivatives as potassium channel openers
US6933308B2 (en) * 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
NZ540446A (en) * 2002-12-27 2008-03-28 Lundbeck & Co As H 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system
EP1603858A2 (en) * 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
JP2006520333A (ja) * 2003-03-14 2006-09-07 ハー・ルンドベック・アクチエゼルスカベット 置換されたアニリン誘導体
AU2004222626B2 (en) * 2003-03-21 2010-06-24 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
EP1631546A1 (en) 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
WO2005025293A2 (en) * 2003-09-10 2005-03-24 Icagen, Inc. Fused ring heterocycles as potassium channel modulators
ATE423128T1 (de) * 2004-02-20 2009-03-15 Nat Ct For Biolog Sciences Neues kaliumkanalmodulierendes peptid
TWI349666B (en) * 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
US7812020B2 (en) * 2005-03-03 2010-10-12 H. Lundbeck A/S Substituted pyridine derivatives
WO2007063418A2 (en) * 2005-04-13 2007-06-07 Neuraxon, Inc. Substituted indole compounds having nos inhibitory activity

Also Published As

Publication number Publication date
EP2554162A1 (en) 2013-02-06
AR059319A1 (es) 2008-03-26
EA200870232A1 (ru) 2009-02-27
IL192745A0 (en) 2009-02-11
AU2007214128B2 (en) 2012-05-17
JP2009525993A (ja) 2009-07-16
CN101378742B (zh) 2013-07-10
NZ569517A (en) 2011-07-29
EA017915B1 (ru) 2013-04-30
CN101378742A (zh) 2009-03-04
MX2008009655A (es) 2008-09-03
TWI453013B (zh) 2014-09-21
US20090118285A1 (en) 2009-05-07
KR20080096659A (ko) 2008-10-31
TW200808296A (en) 2008-02-16
NO20083838L (no) 2008-10-31
BRPI0707495A2 (pt) 2011-05-03
EP1983974A1 (en) 2008-10-29
CA2641564A1 (en) 2007-08-16
AU2007214128A1 (en) 2007-08-16
WO2007090409A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
CA2641564C (en) Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
US20100256145A1 (en) Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
JP7781768B2 (ja) 神経学的および精神障害の治療方法
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
CA2237582C (en) Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
US20180271869A1 (en) Treatment of anxiety disorders and autism spectrum disorders
JP2018516992A (ja) レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
JP2013539767A (ja) 運動障害の治療のためのセロトニン受容体アゴニストの組み合わせ
HK1181676A (en) Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
HK1129593A1 (en) Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia
HK1129593B (en) Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia
AU2010246724B2 (en) Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl- butyramide
AU2006209368A1 (en) New association between agomelatine and a noradrenaline reuptake inhibitor and pharmaceutical compositions containing it
HK1100481A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150202